Alexion is a global biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products.  Alexion developed and markets a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two severe and life-threatening ultra-rare diseases. Alexion is developing other highly innovative product candidates which are being investigated across multiple severe and ultra-rare disorders, including an enzyme replacement therapy for hypophosphatasia (HPP), a genetic, multi-system and life-threatening ultra-rare metabolic disorder.